Show simple item record

dc.contributor.authorKennedy, Oliver J
dc.contributor.authorNeary, M. T.
dc.date.accessioned2022-08-31T11:38:35Z
dc.date.available2022-08-31T11:38:35Z
dc.date.issued2022en
dc.identifier.citationKennedy OJ, Neary MT. Brief Communication on the Impact of β-blockers on Outcomes in Patients Receiving Cancer Immunotherapy. Journal of immunotherapy (Hagerstown, Md : 1997). 2022 Sep 1;45(7):303-6. PubMed PMID: 35947120. Epub 2022/08/11. eng.en
dc.identifier.pmid35947120en
dc.identifier.doi10.1097/cji.0000000000000433en
dc.identifier.urihttp://hdl.handle.net/10541/625559
dc.description.abstractPreclinical studies show that β-adrenergic activation suppresses the immune system and reduces the effectiveness of cancer immunotherapy. As a result, there is considerable interest in using β-blockers (BBs), a cheap and safe class of medication, in combination with immunotherapy to improve outcomes in cancer. This study is a systematic review and meta-analysis of clinical studies. A comprehensive literature search was performed up to May 2022. Studies were included if they reported hazard ratios (HRs) of overall survival (OS), all-cause mortality or progression-free survival (PFS) associated with BBs in patients with solid organ cancer treated with immunotherapy. Study-specific HRs and 95% confidence intervals were pooled in random effects meta-analyses. Nine studies involving over 6350 patients with melanoma, lung, renal, urothelial, or other solid cancers treated with a range of immunotherapies met the inclusion criteria. Across all studies combined, there was no association between concomitant BB use and OS (HR 0.99, 0.83-1.18) or PFS (HR 0.97, 0.89-1.05). In subgroup analyses, BB use made no difference to OS or PFS in melanoma (OS HR 0.66, 0.33-1.34; PFS HR 0.81, 0.62-1.05) or to OS in lung cancer (OS HR 1.00, 0.49-2.07). In summary, this study found no evidence that BBs enhance immunotherapy effectiveness.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1097/cji.0000000000000433en
dc.titleBrief communication on the impact of β-blockers on outcomes in patients receiving cancer immunotherapyen
dc.typeArticleen
dc.contributor.departmentChristie NHS Foundation Trusten
dc.identifier.journalJournal of Immunotherapyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record